Open Label Study of Single Dose Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy.
Phase of Trial: Phase I/II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Rhenium 188 P 2045 (Primary)
- Indications Non-small cell lung cancer; Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bayer; Bayer HealthCare Pharmaceuticals Inc.
- 29 May 2009 New trial record